| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
42,477 |
36,889 |
$3.19M |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
14,621 |
14,306 |
$441K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
4,836 |
4,783 |
$422K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
5,084 |
5,040 |
$404K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
6,702 |
6,441 |
$367K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
3,595 |
3,559 |
$284K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
2,960 |
2,921 |
$221K |
| 87428 |
|
2,790 |
2,731 |
$175K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
5,665 |
5,509 |
$80K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,734 |
1,490 |
$64K |
| 90461 |
|
2,538 |
2,341 |
$59K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
964 |
917 |
$56K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
1,660 |
1,638 |
$53K |
| 92551 |
|
7,398 |
7,210 |
$50K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
747 |
723 |
$42K |
| 95165 |
Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials |
219 |
31 |
$42K |
| 99215 |
Prolong outpt/office vis |
357 |
349 |
$42K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
644 |
621 |
$41K |
| 81002 |
|
12,316 |
11,980 |
$35K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
2,018 |
1,802 |
$30K |
| 0071A |
|
363 |
353 |
$30K |
| 0001A |
|
522 |
509 |
$27K |
| 0002A |
|
479 |
477 |
$26K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
296 |
281 |
$23K |
| 99177 |
|
1,639 |
1,614 |
$22K |
| 0004A |
|
252 |
251 |
$20K |
| 0072A |
|
207 |
207 |
$17K |
| 99402 |
|
385 |
370 |
$16K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
156 |
155 |
$14K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
127 |
127 |
$13K |
| 99173 |
|
7,323 |
7,118 |
$13K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
558 |
546 |
$12K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
303 |
301 |
$11K |
| 96127 |
|
2,025 |
2,023 |
$9K |
| 0124A |
|
119 |
119 |
$9K |
| 94010 |
|
293 |
277 |
$9K |
| 99383 |
|
78 |
76 |
$7K |
| 99000 |
|
724 |
699 |
$5K |
| 99384 |
|
48 |
46 |
$5K |
| 0011A |
|
103 |
103 |
$4K |
| 90620 |
|
919 |
851 |
$3K |
| 0012A |
|
69 |
69 |
$3K |
| 94760 |
|
2,443 |
1,926 |
$2K |
| 86580 |
|
329 |
325 |
$2K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
138 |
125 |
$2K |
| 87807 |
|
118 |
118 |
$2K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,233 |
1,076 |
$1K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
31 |
28 |
$1K |
| 95117 |
|
167 |
49 |
$1K |
| 90686 |
|
5,225 |
4,503 |
$1K |
| 99381 |
|
15 |
15 |
$1K |
| 0074A |
|
12 |
12 |
$996.00 |
| 96160 |
|
145 |
140 |
$497.56 |
| 94761 |
|
172 |
128 |
$334.52 |
| 90651 |
|
1,284 |
1,186 |
$300.00 |
| 90619 |
|
126 |
120 |
$274.59 |
| 90715 |
|
118 |
110 |
$192.84 |
| A7015 |
Aerosol mask, used with dme nebulizer |
155 |
140 |
$148.73 |
| 99188 |
|
12 |
12 |
$129.91 |
| 87070 |
|
440 |
399 |
$114.64 |
| 94150 |
|
364 |
261 |
$83.49 |
| 90672 |
|
354 |
346 |
$28.09 |
| 90677 |
|
91 |
84 |
$13.89 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
157 |
142 |
$6.71 |
| J7510 |
Prednisolone oral, per 5 mg |
12 |
12 |
$0.61 |
| 90670 |
|
1,693 |
1,594 |
$0.02 |
| 90674 |
|
399 |
372 |
$0.00 |
| 3008F |
|
7,336 |
6,640 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
2,555 |
2,327 |
$0.00 |
| 90698 |
|
746 |
695 |
$0.00 |
| 90744 |
|
269 |
248 |
$0.00 |
| 90696 |
|
42 |
40 |
$0.00 |
| 1220F |
|
349 |
349 |
$0.00 |
| 90680 |
|
13 |
13 |
$0.00 |
| 91301 |
|
29 |
22 |
$0.00 |
| 90681 |
|
175 |
161 |
$0.00 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
1,124 |
1,000 |
$0.00 |
| 90710 |
|
371 |
349 |
$0.00 |
| 99072 |
|
495 |
376 |
$0.00 |
| 90734 |
|
676 |
600 |
$0.00 |
| 90633 |
|
520 |
472 |
$0.00 |
| 90685 |
|
38 |
30 |
$0.00 |